Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation

Int J Cancer. 1993 Apr 22;54(1):137-43. doi: 10.1002/ijc.2910540122.


We have investigated the effect of monoclonal antibodies (MAbs) specific for aminopeptidase N/CD13 on the invasion of human metastatic tumor cells into reconstituted basement membrane (Matrigel). The invasion of human metastatic tumor cells (SN12M renal-cell carcinoma, HT1080 fibrosarcoma and A375M melanoma) into Matrigel-coated filters was inhibited by an anti-CD13 MAb, WM15, in a concentration-dependent manner. However, this MAb did not have any effect on tumor-cell adhesion and migration to the extracellular matrices, which may be involved in tumor-cell invasion. MAb WM15 inhibited the degradation of type-IV collagen by tumor cells in a concentration-dependent manner. We also found that WM15 inhibited hydrolysing activities towards substrates of aminopeptidases in 3 different tumor cells. Since our previous study indicated that bestatin, an aminopeptidase inhibitor, was able to inhibit tumor-cell invasion, as well as aminopeptidase activities of murine and human metastatic tumor cells, cell-surface amino-peptidase N/CD13 may be partly involved in the activation mechanism for type-IV collagenolysis to achieve tumor-cell invasion, and anti-CD13 MAb WM15 may inhibit tumor-cell invasion through a mechanism involving its inhibitory action on the aminopeptidase N in tumor cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopeptidases / metabolism*
  • Antibodies, Monoclonal
  • Antigens, CD / metabolism*
  • Antigens, Differentiation, Myelomonocytic / metabolism*
  • CD13 Antigens
  • Cell Adhesion
  • Cell Movement
  • Extracellular Matrix / metabolism*
  • Humans
  • In Vitro Techniques
  • Neoplasm Invasiveness*
  • Neoplasm Metastasis*
  • Tumor Cells, Cultured


  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Aminopeptidases
  • CD13 Antigens